To determine if a one year treatment Losartan with or without HCTZ at different dosages have an effect on metabolic parameters in patients with hypertension and the metabolic syndrome.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
1,738
All patients received Losartan 50mg at Visit 2 titrated to Losartan 100mg (if target BP not achieved) titrated to Losartan 100mg + HCTZ 12.5mg (if necessary) up to Losartan 100mg + HCTZ 25mg. Duration of treatment was one year.
Change in Hemoglobin A1c Between 52 Weeks and Baseline
Absolute Change in Hemoglobin A1c between 52 week measurement and baseline value.
Time frame: 52 Weeks - Baseline
Change in Fasting Blood Glucose Between Baseline and 52 Weeks Assessments
Absolute Change in Fasting Blood Glucose Measurements between Baseline and 52 week assessments.
Time frame: 52 Weeks - Baseline
Target Blood Pressure
Target Blood Pressure defined as Systolic Blood Pressure/Diastolic Blood Pressure ≤ 140/90 mm Hg at 52 weeks
Time frame: 52 Weeks
Change in Systolic Blood Pressure Between Baseline and 52 Week Assessments
Absolute change in Systolic Blood Pressure between baseline and 52 week assessments.
Time frame: 52 Weeks - Baseline
Change in Diastolic Blood Pressure Between Baseline and 52 Week Assessments
Absolute change in Diastolic Blood Pressure between baseline and 52 week assessments.
Time frame: 52 Weeks - Baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.